<DOC>
	<DOCNO>NCT00122603</DOCNO>
	<brief_summary>The purpose study evaluate virological efficacy safety two double protease inhibitor regimen : atazanavir/fosamprenavir/ritonavir 300 mg daily/ 700/100 mg twice daily , versus atazanavir/saquinavir/ritonavir 300/1500/100 mg daily protease inhibitor naive HIV-1 patient .</brief_summary>
	<brief_title>Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy HIV-1 Infected Patients ( ANRS127 )</brief_title>
	<detailed_description>The purpose randomize , open-label study evaluate virological efficacy safety two double protease inhibitor regimen : atazanavir/fosamprenavir/ritonavir 300 mg daily/ 700/100 mg twice daily , versus atazanavir/saquinavir/ritonavir 300/1500/100 mg daily protease inhibitor naive HIV-1 patient . Patients CD4 cell count equal 200/mm3 , HIV viral load 10,000 750,000 copy per milliliter , wild-type genotype baseline eligible . This multicenter study enroll 60 patient ( n=30 group ) . The planned duration study 48 week enrolment last subject . The primary efficacy endpoint virologic success define HIV RNA level 50 copies/ml 16 week initial treatment . The durability response evaluate patient follow 48 week . The primary safety endpoint treatment interruption adverse effect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>Protease inhibitor naive patient Wild type genotype CD4 great 200/mm3 Viral load 10,000 copies/ml 750,000 copies/ml Signed informed consent Pregnancy ; breast feeding Antiretroviral ( ARV ) pretreated patient Hyperlipidemic treatment Evolutive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Atazanavir</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Fosamprenavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>